Skip to main content

Table 1 Responders demographics, classification and reduction in migraine days per month

From: Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders

 

Demographics

% of migraine days per month

Response

 

Age

Years w/migraine

Gender

BMI

MIDAS

Classification

Baseline

1 month

2 months

3 months

% reduction (3 months vs baseline)

Patient 1

22

11

Female

37.6

moderate

EM (HF)

32.1

10.0

9.7

8.0

71.3

Patient 2

32

11

Female

23.9

severe

EM (LF)

26.2

13.3

6.5

6.3

66.9

Patient 3

28

20

Male

21.2

moderate

EM (LF)

25.6

12.5

15.4

0.0

63.7

Patient 4

34

7

Female

36

severe

EM (HF)

42.4

13.0

4.3

37.5

56.9

Patient 5

54

9

Female

29.8

severe

EM (HF)

45.5

33.3

12.5

20.0

51.7

Patient 6

27

3

Female

26.5

severe

EM (HF)

48.6

52.6

5.3

14.7

50.2

Patient 7

40

21

Male

25.1

severe

EM (HF)

47.1

26.1

25.0

5.3

60.1

Patient 8

38

26

Female

26.7

moderate

EM (HF)

31.1

4.0

0.0

0.0

95.7

Patient 9

30

13

Male

19.2

moderate

EM (HF)

28.0

8.5

16.7

2.6

66.9

Patient 10

46

35

Male

28.4

severe

EM (HF)

39.3

37.5

20.0

0.0

51.2

Patient 11

49

34

Female

22.9

moderate

EM (HF)

47.1

18.5

7.1

11.1

74.0

Patient 12

27

1

Female

19.5

severe

EM (HF)

39.3

14.3

3.2

6.5

79.7

Patient 13

24

13

Female

24.2

severe

EM (HF)

36.7

30.3

10.3

13.1

51.2

Patient 14

37

22

Female

22.3

severe

EM (HF)

36.8

4.2

14.3

8.3

75.8

Patient 15

42

28

Female

23.8

severe

EM (HF)

41.4

10.3

13.8

20.0

64.4

Patient 16

36

3

Female

25.8

severe

EM (HF)

35.1

9.5

4.8

27.3

60.6

Patient 17

23

5

Female

37

severe

EM (HF)

39.1

20.0

17.9

10.3

58.9

Patient 18

25

13

Female

25

severe

EM (HF)

42.1

16.7

13.3

21.4

59.3

Patient 19

27

20

Male

24.4

severe

EM (HF)

33.3

20.0

9.4

0.0

70.6

Patient 20

25

17

Female

21

severe

CM

83.9

22.7

28.1

17.4

72.9

Patient 21

26

10

Female

23

severe

CM

64.6

7.1

4.2

3.3

92.4

Patient 22

39

15

Female

25.7

severe

CM

50.0

15.4

13.3

6.9

76.3

Patient 23

32

2

Female

25.1

mild

CM

63.6

36.7

35.7

13.3

55.1

Patient 24

34

25

Female

25.5

severe

CM

50.0

11.1

17.6

21.4

66.5

Patient 25

41

20

Female

25.1

severe

CM

57.1

32.3

20.7

17.2

59.1

Patient 26

21

10

Female

18.5

severe

CM

85.7

38.5

8.3

16.7

75.3

Patient 27

26

8

Female

25.9

severe

CM

59.4

9.5

9.5

7.1

85.3